Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €3.48 EUR
Change Today -0.085 / -2.38%
Volume 350.0
GERN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 1:29 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

149 Commonwealth Drive

Suite 2070

Menlo Park, CA 94025

United States

Phone: 650-473-7700

Fax: 650-473-7750

Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The discovery and early development of imetelstat, the company’s sole product candidate, was based on its core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Imetelstat is a potent and specific inhibitor of telomerase. Using the company’s proprietary nucleic acid chemistry, it designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. The company owns exclusive worldwide commercial rights with U.S. patent coverage extending through 2025. The Myelofibrosis (MF) IST is also evaluating imetelstat in patients with refractory anemia with ringed sideroblasts, a subpopulation of myelodysplastic syndromes, and patients with MF that has transformed into acute myelogenous leukemia, known as blast-phase MF. In March 2014, the company received written notice from the U.S. Food and Drug Administration, or the FDA, that its Investigational New Drug application for imetelstat has been placed on full clinical hold following their review of data related to hepatotoxicity in its then-ongoing clinical studies. Telomerase is a naturally occurring enzyme that maintains telomeres and prevents them from shortening during cell division in cells, such as stem cells, that must remain immortalized to support normal health. Telomerase consists of at least two essential components: an RNA template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA sequence to the chromosome ends. Telomerase is active during embryonic development, enabling the rapid cell division that supports normal growth. During the latter stages of human fetal development and in adulthood, telomerase is repressed in most cells, and telomere length gradually decreases during a lifetime. In tissues that have a high turnover throughout life, such as blood and gut, telomerase can be transiently upregulated in progenitor cells to enable controlled, self-limited proliferation to replace cells lost through natural cell aging processes. In proliferating progenitor cells, relatively long telomeres are maintained by upregulated telomerase. As the progeny of progenitor cells mature, telomerase is downregulated and telomeres shorten with cell division, preventing uncontrolled proliferation. Imetelstat is a lipid-conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity. Myeloproliferative neoplasms, or MPNs, are hematologic myeloid malignancies that arise from malignant hematopoietic myeloid progenitor cells in the bone marrow, such as the precursor cells of red blood cells, platelets and granulocytes. MF is a myeloproliferative neoplasm among related diseases, such as essential thrombocythemia, and is characterized by clonal proliferation of malignant hematopoietic progenitor cells in the bone marrow that causes bone marrow fibrosis, elevation in bone density, known as osteosclerosis, and abnormal rapid proliferation of blood vessels, known as pathological angiogenesis. MF patients can also suffer from debilitating constitutional symptoms, such as drenching night sweats, fatigue, severe itching, known as pruritus, fever and bone pain. Significant Events In 2013, the company closed the transaction to divest its human embryonic stem cell assets and its autologous cellular immunotherapy program pursuant to the terms of the Contribution Agreement it entered into with BioTime, Inc. and Asterias Biotherapeutics, Inc. in January 2013. Intellectual Property The company’s patent rights for imetelstat include those covering the nucleic acid sequence of hTR, the RNA component o

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:GR €3.48 EUR -0.085

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.39 USD 0.00
BioTime Inc $5.19 USD -0.25
IntelliCell BioSciences Inc $0.0001 USD 0.00
Neuralstem Inc $1.76 USD -0.11
ReNeuron Group PLC 4.65 GBp +0.15
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 509.2x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 390.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.